Ganløse Dyreklinik ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  4.0% 9.4% 2.9% 2.2% 1.8%  
Credit score (0-100)  51 26 57 66 71  
Credit rating  BBB BB BBB BBB A  
Credit limit (kDKK)  0.0 0.0 0.0 0.1 1.6  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  2,752 2,521 3,800 4,054 4,252  
EBITDA  596 -294 578 766 387  
EBIT  499 -331 503 675 258  
Pre-tax profit (PTP)  498.0 -339.0 494.0 658.0 246.7  
Net earnings  385.0 -267.0 384.0 511.0 188.2  
Pre-tax profit without non-rec. items  498 -339 494 658 247  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  98.0 111 459 391 302  
Shareholders equity total  435 167 552 962 1,051  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,320 1,566 1,603 2,127 1,993  

Net Debt  -590 -795 -431 -1,069 -1,159  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  2,752 2,521 3,800 4,054 4,252  
Gross profit growth  0.0% -8.4% 50.7% 6.7% 4.9%  
Employees  3 0 0 0 7  
Employee growth %  0.0% -100.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,320 1,566 1,603 2,127 1,993  
Balance sheet change%  0.0% 18.6% 2.4% 32.7% -6.3%  
Added value  596.0 -294.0 578.0 750.0 387.3  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  1 -24 273 -159 -218  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  1.0 -1.0 1.0 2.0 3.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  18.1% -13.1% 13.2% 16.7% 6.1%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  38.1% -22.8% 31.8% 36.2% 12.5%  
ROI %  115.4% -109.1% 137.0% 87.3% 25.4%  
ROE %  88.5% -88.7% 106.8% 67.5% 18.7%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  33.0% 10.7% 34.4% 45.2% 52.7%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -99.0% 270.4% -74.6% -139.6% -299.3%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  1.0 0.8 0.7 1.1 1.5  
Current Ratio  1.4 1.0 1.1 1.5 1.8  
Cash and cash equivalent  590.0 795.0 431.0 1,069.0 1,159.2  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  334.0 52.0 106.0 583.0 752.1  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  199 0 0 0 55  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  199 0 0 0 55  
EBIT / employee  166 0 0 0 37  
Net earnings / employee  128 0 0 0 27